FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, L2
FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Enters Merger Agreement with Actio Biosciences
To Acquire, Expanding Rare Epilepsy Portfolio
Second Quarter 2026 Financial Results Announced
Results of Shareholder Votes at 2026 Annual General Meeting
Annual Report to Security Holders
Director Departure - Anne O’Riordan Will Not Stand for Re-Election
Announces First Quarter 2026 Financial Results
Q2
Q1
Amended Annual Report
FY 2024
Q3
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party